Objective Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19. Results Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6–15) for the convalescent plasma group and 7 days (IQR 5–9) for the standard of care group ( p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died ( p = 0.64, OR 0.49, 95% CI 0.08–2.79). Thus no significant differences were observed between the groups. Trial registration ClinicalTrials NCT04600440, retrospectively registered Oct 23, 2020. Supplementary Information The online version contains supplementary material available at 10.1186/s13104-021-05847-7.
【저자키워드】 COVID-19, convalescent plasma, SARS-CoV2, Desaturation, Oxygen therapy, 【초록키워드】 therapy, viral infections, observational study, Randomized, oxygen saturation, Patient, plasma, hospitalized COVID-19 patient, Standard of care, Oxygen treatment, Primary outcome, supplementary material, 95% CI, no significant difference, median time, Registered, convalescent plasma group, convalescent plasma treatment, survivor, randomized controlled study, Inclusion, objective, Result, died, addition, median, Two patient, hospitalized patient, groups, receive, 1:1, IQR, with COVID-19, 【제목키워드】 Treatment, Open-label, Randomized, convalescence, plasma,